APA (7th ed.) Citation

Merle, P., Finn, R. S., Kudo, M., Klümpen, H., Lim, H. Y., Pinter, M., . . . Qin, S. (2024). Analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) and Child-Pugh (CP)-B liver function treated with regorafenib in routine clinical practice in the observational REFINE study. Journal of clinical oncology, 42(3_suppl), 452. https://doi.org/10.1200/JCO.2024.42.3_suppl.452

Chicago Style (17th ed.) Citation

Merle, Philippe, et al. "Analysis of Patients (pts) with Unresectable Hepatocellular Carcinoma (uHCC) and Child-Pugh (CP)-B Liver Function Treated with Regorafenib in Routine Clinical Practice in the Observational REFINE Study." Journal of Clinical Oncology 42, no. 3_suppl (2024): 452. https://doi.org/10.1200/JCO.2024.42.3_suppl.452.

MLA (9th ed.) Citation

Merle, Philippe, et al. "Analysis of Patients (pts) with Unresectable Hepatocellular Carcinoma (uHCC) and Child-Pugh (CP)-B Liver Function Treated with Regorafenib in Routine Clinical Practice in the Observational REFINE Study." Journal of Clinical Oncology, vol. 42, no. 3_suppl, 2024, p. 452, https://doi.org/10.1200/JCO.2024.42.3_suppl.452.